A Phase II Study of Apatinib in Patients with Chemotherapy‐Refractory Esophageal Squamous Cell Carcinoma (ESO‐Shanghai 11)

LESSONS LEARNED: Apatinib has potential as an effective and safe second‐line or higher treatment for patients with chemotherapy‐refractory esophageal squamous cell carcinoma (ESCC). Clinical safety is of potential concern when administering apatinib to patients with uncontrolled esophageal lesions o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Chu, Li, Chen, Yun, Liu, Qi, Liang, Fei, Wang, Shengping, Liu, Quan, Yu, Hui, Wu, Xianghua, Zhang, Junhua, Deng, Jiaying, Ai, Dashan, Zhu, Zhengfei, Nie, Yongzhan, Zhao, Kuaile
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley & Sons, Inc. 2021
Schlagworte:
Clinical Trial Results
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8176978/
https://ncbi.nlm.nih.gov/pubmed/33393167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13668
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge